Gabelli Funds LLC Sells 1,250 Shares of Stryker Co. (NYSE:SYK)

Gabelli Funds LLC lowered its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 1.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 114,524 shares of the medical technology company's stock after selling 1,250 shares during the quarter. Gabelli Funds LLC's holdings in Stryker were worth $41,234,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chicago Capital LLC boosted its holdings in Stryker by 3.1% during the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares in the last quarter. Zhang Financial LLC raised its position in shares of Stryker by 55.0% during the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after purchasing an additional 40,784 shares during the period. Appleton Partners Inc. MA lifted its holdings in shares of Stryker by 5.0% during the fourth quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock valued at $10,521,000 after purchasing an additional 1,400 shares during the last quarter. Metis Global Partners LLC increased its stake in Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after purchasing an additional 1,561 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Stryker by 0.5% during the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company's stock valued at $65,829,000 after buying an additional 976 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

Shares of NYSE:SYK traded down $0.21 during midday trading on Friday, hitting $346.46. The company's stock had a trading volume of 1,349,873 shares, compared to its average volume of 1,362,954. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $132.24 billion, a price-to-earnings ratio of 44.65, a PEG ratio of 2.93 and a beta of 0.93. The stock's 50 day simple moving average is $371.83 and its 200 day simple moving average is $373.11.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company posted $3.46 EPS. As a group, research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Barclays raised their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. JPMorgan Chase & Co. upped their price target on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.